Author Index for Volume 22

Abel, R, 269
Abrams, D, 176
Adrogue, H, 674
Albert, DM, 248
ALBI Study Group, 639
Alioto, ME, 236S
Alldredge, BK, 290
Allen, F, 290
ALLHAT Collaborative Research Group, 29, 659, 674
Alston, B, 49
Arad, Y, 553
Arlinger, K, 515
Armstrong, TJ, 181S, 196S
Asthma Clinical Research Network, 119S, 126S, 135S, 156S, 168S, 181S, 196S, 207S, 222S, 236S, 244S

Ball, K, 453
Barkhuizen, A, 310
Barzilay, J, 659
Bellissant, E, 503
Bender, R, 102
Bertin, S, 538
Besch, CL, 176
Bettencourt, J, 29
Bhandari, M, 687
Bijnens, L, 538
Boehmer, SJ, 168S
Boers, M, 89
Bourhis, J, 538
Boushey, HA, 236S
Bowen, DJ, 279
Britton, TB, 181S, 196S
Brizz, B, 176
Busse, WW, 405
Buxton, M, 420
Bycott, P, 269

CAPS Team, 333
Carey, M, 367
Chan, V, 117
Chang, I, 438
Chartier, K, 269
Chen, L, 176
Chen, Y-Z, 405
Chêne, G, 639
Cherniack, RM, 119S, 156S
Cheshire, K, 13
Chinchilli, VM, 117S, 119S, 126S, 135S, 156S, 244S
Clauw, DJ, 310
Clax, P, 485
Collaborative Ocular Melanoma Study Group, 248, 526
Collaborative Ocular Melanoma Study COMS Mortality Coding Committee, 248
Colon, P, 659
Colton, T, 261
COMET Group, 573
Corry, M, 290
CPCRA 058 FIRST Trial Study Team, 176
CSP #470 Study Group, 310
Cumberland, WG, 373
Curley, RM, 135S, 156S
Cushman, WC, 659

Davis, BR, 29, 659, 674
Day, S, 264, 401
Deger, GE, 659
DeGruttola, VG, 142, 485
DeMets, DL, 192, 485
Deswal, A, 605
Diener-West, M, 248, 526
Dixon, DO, 548
Donta, ST, 310
Downing, GJ, 485
Drazen, JM, 126S, 196S
Driver, B, 199
Duchateau, L, 538
Dugan, E, 279
Dyer, A-M, 168S, 207S

Earle, JD, 526
Edler, L, 261
Egan, D, 659, 674
Ellenberg, JH, 49
Ellenberg, SS, 485
Engle, CC Jr, 310
ESPRIT Executive Committee, 42
ESPRIT Vanguard Group, 42
Evans, RL, 135S, 156S
Evans, S, 261

Fahy, J, 207S
Farber, M, 674
Feigal, D, 139
Feussner, JR, 310
Fish, JE, 126S, 244S
Folmar, S, 13
Forand, PE, 168S, 181S, 196S
Ford, CE, 29
Ford, JG, 222S
Fosdick, L, 42
Freret, N, 689
Friedman, L, 485
Friedman, MJ, 74
Frolkis, J, 659
Furberg, CD, 29

Gail, MH, 485
Gelb, A, 290
Geller, N, 261
George, S, 261
Geraci, TS, 29
Goldberg, RM, 117
Gong, J, 192
Gottwald, M, 290
Grambsch, P, 56
Grandits, GA, 56
Greenspan, AI, 689
Grimm, RH Jr, 56
Guarino, P, 310
Guerci, AD, 553
Gwiazda, J, 573

Hackell, JG, 438
Hartung, J, 111
Hawkins, BS 526
Helmers, KF, 453
Herrington, D, 13
Hess, HM, 156S
Hoekstra, OS, 89
Holbrook, JT, 62

Controlled Clinical Trials 22:705–707 (2001)

© Elsevier Science Inc. 2001

655 Avenue of the Americas, New York, NY 10010

0197-2456/01/$–see front matter

Holland, LA, 56
Horton, R, 593
Hsieh, FY, 74
Hunt, JR, 279
Hurd, SS, 119S
Hussein, M, 573
Hutton, J, 261
Hyman, L, 573

Initio Co-ordinating Committee, 160
Isaacs, SM, 290
Israel, E, 196S, 244S

Jabs, DA, 62
Jacqmin-Gadda, H, 639
Janson, SL, 236S
Jobe, JB, 453
Joly, P, 639
Journot, V, 639
Juneau, P, 269
Jung, S-H, 367

Käppi, M, 515
Kaylor, J, 135S
Kazis, LE, 310
Kephart, DK, 119S, 207S
Kim, KM, 195, 367
Kimmel, B, 29
Kingry, C, 29
Klein, KP, 13
Kleinman, K, 2, 453
Kohberger, R, 438
Kraft, M, 207S
Kunselman, SJ, 168S, 181S, 196S
Kutner, M, 689
Kuznetsova, OM, 69

Lachenbruch, P, 261
Lamm, CJ, 420
La Moreaux, L, 269
Lavori, PW, 74
Lazarus, SC, 126S
Lee, JJ, 390
Leeder, SR, 333
Leenen, FHH, 659
Lemanske, RF Jr, 126S, 222S
Letterer, R, 659
Leung, DH-Y, 126
Leveck, MD, 453
Liljas, B, 420
Louis, GT, 674
Louis, TA, 266
Lowenstein, DH, 290
Lucente, T, 659
Ludlam, SE, 279
Lui, K-J, 373
Lusk, C, 29

MacArthur, RD, 176
Macer, J, 13
Marks, GB, 333
Marsh-Tootle, WL, 573
Marsiske, M, 453
Martin, RJ, 126S, 207S
Matsuyama, Y, 620
Mauger, DT, 244S
Mauger, EA, 244S
Mayers, DL, 176
McCaffrey, LD, 248
Meinert, CL, 62
Mellis, CM, 333
Menendez, E, 238
Mihrshahi, S, 333
Molina, J-M, 639
Morris, JN, 453
Moulton, LH, 438
Moy, CS, 248, 526
Moyé, LA, 605
Murray, G, 261
Muth, K, 49

Naughton, MJ, 279
Neaton, JD, 27
Neuhaus, J, 290
Newstein, D, 553
Norton, TT, 573
Novak, R, 176
Nwachuku, C, 29, 659

Oates-Williams, F, 13
O'Brien, KL, 438
O'Byrne, PM, 405, 420
O'Grady, M, 689
Ohashi, Y, 620
Ohlsson, SV, 405
O'Neil, N, 290

Pan, W, 211
Parks, H, 29
Paulissen, J, 269
Pauwels, RA, 405
Payne, G, 674
Peat, JK, 333
Pedersen, S, 405
Peduzzi, P, 310
Peng, G, 176
Pennello, G, 548
Pignon, JP, 538
Pillari, A, 196S
Piller, LB, 29
Pinheiro, JC, 192
PLUS Study Group, 89
Pogash, RM, 135S, 168S
Prentice, R, 485
Pressel, SL, 29, 659, 674
Prineas, RJ, 56
Probstfield, J, 674
Proschan, M, 550
Pullman, D, 203

Rahlfs, VW, 191
Ranstam, J, 261
Rebok, GW, 453
Rebousssin, D, 13
Reid, R, 438
Ricci, L, 689
Richards, RR, 687
Robbins, GK, 142
Rosal, MC, 279
Roth, M, 553

Salamon, R, 639
Santosham, M, 438
Sargent, DJ, 117
Sarr, M, 72
Sattin, RW, 689
Savès, M, 639
Schall, R, 402
Schemitsch, EH, 687
Scherrer, B, 261
Schmetter, B, 176
Schnurr, PP, 74
Scully, RE, 248
Sébille, V, 503
Shafer, RW, 142
Sharp, P, 13
Shih, WJ, 357
Shumaker, SA, 279
Siber, GR, 438
Simpson, LM, 29
Sjöström, L, 515
Skinner, JS, 310
Smeaton, LM, 142
Smit, EF, 89
Smith, DM, 453
Smith, J, 13
Sorkness, CA, 222S
Sprague, S, 687
Spino, C, 269
Stevens, S, 279
Studies of Ocular Complications of AIDS Research Group, 62
Sullivan, SD, 420
Sylvester, R, 538

Tan, WC, 405, 420
Tavel, JA, 42
Tennstedt, SL, 453
Tobin, JN, 659
Torgerson, JS, 515
Tovey, ER, 333
Toyoda, I, 620

Tseng, C-H, 390
Tulsky, JP, 238

Ullman, A, 405
Ulrich, S, 290

van den Berg-Wolf, M, 176
van Tinteren, H, 89
Verboom, P, 89

Waclawiw, M, 550
Walsh, S, 659
Wang, X, 203
Wang, Y-G, 126
Ward, H, 674
Weatherholtz, R, 438
Webb, K, 333
Weiss, KB, 420
Whelton, P, 674
White, MC, 238
Wilcox, S, 279
Willan, AR, 228
Williams, DA, 310
Willis, SL, 453
Willson, JKV, 248
Wittes, J, 485
Wolf, SL, 689
Wright, JT Jr, 29, 659

Xu, T, 689

Yan, C, 269
Yu, E, 49
Yurik, T, 176

Zeger, SL, 485

ELSEVIER

Subject Index for Volume 22

ABSOLUTE RISK REDUCTION
Calculating Confidence Intervals for the Number Needed to Treat, 102

ACTIVITIES OF DAILY LIVING
ACTIVE: A Cognitive Intervention Trial to Promote Independence in Older Adults, 453

ADAPTIVE DOUBLE DATA ENTRY
Adaptive Double Data Entry: A Probabilistic Tool for Choosing Which Forms to Reenter, 2

ADAPTIVE INTERIM ANALYSES
A Self-Designing Rule for Clinical Trials with Arbitrary Response Variables, 111

ADHERENCE
Promoting Adherence and Retention to Clinical Trials in Special Populations: A Women's Health Initiative Workshop, 279

AFRICAN AMERICANS
See Minorities.

AGING
ACTIVE: A Cognitive Intervention Trial to Promote Independence in Older Adults, 453
A Study Design to Investigate the Effect of Intense Tai Chi in Reducing Falls among Older Adults Transitioning to Frailty, 689

AIDS. *See* HIV

ALLERGEN AVOIDANCE
The Childhood Asthma Prevention Study (CAPS): Design and Research Protocol of a Randomized Trial for the Primary Prevention of Asthma, 333

ALLOCATION
Implementing Randomization Procedures in the Asthma Clinical Research Network, 181S
Trials within Trials: Confirmatory Subgroup Analyses in Controlled Clinical Experiments, 605

ALPHA INTERFERON
The Closeout Process for a Clinical Trial Terminated Early for Lagging Enrollment and Inadequate Follow-up, 49

ANTIHYPERTENSIVES
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical Center Recruitment Experience, 659
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29
Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 674

ANTIOXIDANTS
Rationale and Design of the St. Francis Heart Study: A Randomized Clinical Trial of Atorvastatin Plus Antioxidants in Asymptomatic Persons with Elevated Coronary Calcification, 553

ANTIRETROVIRAL THERAPY. *See also* HIV
ACTG (AIDS Clinical Trials Group) 384: A Strategy Trial Comparing

Controlled Clinical Trials 22:709–719 (2001)
© Elsevier Science Inc. 2001
655 Avenue of the Americas, New York, NY 10010

0197-2456/01/$–see front matter

Consecutive Treatments for HIV-1, 143
An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1 Infection: Design, Rationale, and Methods of the Initio Trial, 160
The Rationale and Design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial, 176
Viral Load as a Primary Outcome in Human Immunodeficiency Virus Trials: A Review of Statistical Analysis Methods, 639
Who's on First? What's on Second? 139

ASTHMA

Attrition and Retention of Ethnically Diverse Subjects in a Multicenter Randomized Controlled Research Trial, 236S
The Childhood Asthma Prevention Study (CAPS): Design and Research Protocol of a Randomized Trial for the Primary Prevention of Asthma, 333
The Clinical Trials in the Initial Five-Year Award Period of the Asthma Clinical Research Network, 126S
Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial, 420
Genetic Analysis in the Asthma Clinical Research Network, 196S
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405
Modem Remote Support of Pulmonary-Function Testing and Quality Control Systems, 156S
The Organization of the Asthma Clinical Research Network: A Multicenter, Multiprotocol Clinical Trials Team, 119S
Quality Control within the Asthma Clinical Research Network, 207S
Summarizing Methacholine Challenges in Clinical Research, 244S

ATHEROSCLEROSIS

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical Center Recruitment Experience, 659
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29
Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 674
Rationale and Design of the St. Francis Heart Study: A Randomized Clinical Trial of Atorvastatin Plus Antioxidants in Asymptomatic Persons with Elevated Coronary Calcification, 553
Recruitment of Participants for the Estrogen Replacement and Atherosclerosis (ERA) Trial: A Comparison of Costs, Yields, and Participant Characteristics from Community- and Hospital-Based Recruitment Strategies, 13

ATOPY

The Childhood Asthma Prevention Study (CAPS): Design and Research Protocol of a Randomized Trial for the Primary Prevention of Asthma, 333

ATTRITION

Attrition and Retention of Ethnically Diverse Subjects in a Multicenter Randomized Controlled Research Trial, 236S
Locating Study Subjects: Predictors and Successful Search Strategies with Inmates Released from a U.S. County Jail, 238

AUTOPSY

Cause-Specific Mortality Coding: Methods in the Collaborative Ocular Melanoma Study COMS Report No. 14, 248

BEHAVIORAL THERAPY

ACTIVE: A Cognitive Intervention Trial to Promote Independence in Older Adults, 453

A Multicenter Two by Two Factorial Trial of Cognitive Behavioral Therapy and Aerobic Exercise for Gulf War Veterans' Illnesses: Design of a Veterans Affairs Cooperative Study (CSP #470), 310

BENZODIAZEPINES
The Prehospital Treatment of Status Epilepticus (PHTSE) Study: Design and Methodology, 290

BIOMARKERS
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop, 485

BOOK REVIEWS
Design and Analysis of Bioavailability and Bioequivalence Studies, 2nd Ed., 402
Encyclopedia of Biopharmaceutical Statistics, 269
Group Sequential Methods with Applications to Clinical Trials, 195
Manual for Clinical Trials Nursing, 199
Meta-Analysis in Medicine and Health Policy, 266
Rational Diagnosis and Treatment: Evidence Based Clinical Decision-Making, 73

BRONCHIAL REVERSIBILITY
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405

BUDESONIDE
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405

CERTIFICATION
Quality Control within the Asthma Clinical Research Network, 207S

CHOLESTEROL. *See* LIPID-LOWERING TREATMENTS

CHOROIDAL MELANOMA
Cause-Specific Mortality Coding: Methods in the Collaborative Ocular Melanoma Study COMS Report No. 14, 248

CLOSEOUT PROCESS
Closeout of Four Phase II Vanguard Trials and Patient Rollover into a Large International Phase III HIV Clinical Endpoint Trial, 42
The Closeout Process for a Clinical Trial Terminated Early for Lagging Enrollment and Inadequate Follow-up, 49
Obtaining Event Status at the Close of the Treatment of Mild Hypertension Study: Methods and Implications for Other Trials, 56
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29
Patient Notification and Follow-up after Suspension of Treatment Protocols: Experience from Four Clinical Trials of Treatments for AIDS-Related CMV Retinitis, 62

CMV RETINITIS
Patient Notification and Follow-up after Suspension of Treatment Protocols: Experience from Four Clinical Trials of Treatments for AIDS-Related CMV Retinitis, 62

COGNITIVE THERAPY
ACTIVE: A Cognitive Intervention Trial to Promote Independence in Older Adults, 453
A Multicenter Two by Two Factorial Trial of Cognitive Behavioral Therapy and Aerobic Exercise for Gulf War Veterans' Illnesses: Design of a Veterans Affairs Cooperative Study (CSP #470), 310

COLCHICINE
The Clinical Trials in the Initial Five-Year Award Period of the Asthma Clinical Research Network, 126S

CONFIDENCE INTERVAL
Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data, 228

Calculating Confidence Intervals for the Number Needed to Treat, 102

CONSISTENCY TRIALS
Clinical Trials for Drug Registrations in Asian-Pacific Countries: Proposal for a New Paradigm from a Statistical Perspective, 357

CONTINUAL REASSESSMENT METHOD
Isotonic Designs for Phase I Trials, 126

COST-EFFECTIVENESS
Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data, 228
Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial, 420
Toward Less Futile Surgery in Non-Small Cell Lung Cancer? A Randomized Clinical Trial to Evaluate the Cost-Effectiveness of Positron Emission Tomography, 89

CULTURAL DIFFERENCES. *See* MINORITIES

DATA MANAGEMENT
Adaptive Double Data Entry: A Probabilistic Tool for Choosing Which Forms to Reenter, 2
Data Management Procedures in the Asthma Clinical Research Network, 168S
Development and Deployment of an Internet-Based Data Management System for Use by the Asthma Clinical Research Network, 135S

DESIGN PAPERS
ACTG (AIDS Clinical Trials Group) 384: A Strategy Trial Comparing Consecutive Treatments for HIV-1, 143
ACTIVE: A Cognitive Intervention Trial to Promote Independence in Older Adults, 453
The Childhood Asthma Prevention Study (CAPS): Design and Research Protocol of a Randomized Trial for the Primary Prevention of Asthma, 333
The Correction of Myopia Evaluation Trial (COMET): Design and General Baseline Characteristics, 573
Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial, 420
Design of a Group-Randomized *Streptococcus pneumoniae* Vaccine Trial, 438
Design of Department of Veterans Affairs Cooperative Study No. 420: Group Treatment of Posttraumatic Stress Disorder, 74
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405
A Multicenter Two by Two Factorial Trial of Cognitive Behavioral Therapy and Aerobic Exercise for Gulf War Veterans' Illnesses: Design of a Veterans Affairs Cooperative Study (CSP #470), 310
An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1 Infection: Design, Rationale, and Methods of the Initio Trial, 160
The Prehospital Treatment of Status Epilepticus (PHTSE) Study: Design and Methodology, 290
The Rationale and Design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial, 176
Rationale and Design of the St. Francis Heart Study: A Randomized Clinical Trial of Atorvastatin Plus Antioxidants in Asymptomatic Persons with Elevated Coronary Calcification, 553
A Study Design to Investigate the Effect of Intense Tai Chi in Reducing Falls among Older Adults Transitioning to Frailty, 689
Toward Less Futile Surgery in Non-Small Cell Lung Cancer? A Randomized Clinical Trial to Evaluate the Cost-Effectiveness of Positron Emission Tomography, 89

DIABETES
Principles for Enhanced Recruitment of Subjects in a Large Clinical Trial: The XENDOS Study Experience, 515

DIAGNOSTIC IMAGING
Toward Less Futile Surgery in Non-Small Cell Lung Cancer? A Randomized Clinical Trial to Evaluate the Cost-Effectiveness of Positron Emission Tomography, 89

DIAZEPAM
The Prehospital Treatment of Status Epilepticus (PHTSE) Study: Design and Methodology, 290

DOSE ESCALATION
Isotonic Designs for Phase I Trials, 126

DOXAZOSIN
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29

DROPOUT
Estimation and Comparison of Rates of Change in Repeated-Measures Studies with Planned Dropout, 620

DRUG REGISTRATION
Clinical Trials for Drug Registrations in Asian-Pacific Countries: Proposal for a New Paradigm from a Statistical Perspective, 357

EARLY TERMINATION
The Closeout Process for a Clinical Trial Terminated Early for Lagging Enrollment and Inadequate Follow-up, 49
Graphical Search for Two-Stage Designs for Phase II Clinical Trials, 367
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29

ELDERLY. *See* AGING

EMERGENCY MEDICAL SERVICES
The Prehospital Treatment of Status Epilepticus (PHTSE) Study: Design and Methodology, 290

ENDPOINT MEASUREMENT
Trials within Trials: Confirmatory Subgroup Analyses in Controlled Clinical Experiments, 605

EQUIVALENCE
Calculating Confidence Intervals for the Number Needed to Treat, 102
Sample Size Determination for Equivalence Test Using Rate Ratio of Sensitivity and Specificity in Paired Sample Data, 373

ESTROGEN REPLACEMENT
Recruitment of Participants for the Estrogen Replacement and Atherosclerosis (ERA) Trial: A Comparison of Costs, Yields, and Participant Characteristics from Community- and Hospital-Based Recruitment Strategies, 13

ETHICS
Adaptive Designs, Informed Consent, and the Ethics of Research, 203
The Clinical Trial: Deceitful, Disputable, Unbelievable, Unhelpful, and Shameful—What Next?, 593

EXERCISE
A Multicenter Two by Two Factorial Trial of Cognitive Behavioral Therapy and Aerobic Exercise for Gulf War Veterans' Illnesses: Design of a Veterans Affairs Cooperative Study (CSP #470), 310
A Study Design to Investigate the Effect of Intense Tai Chi in Reducing Falls among Older Adults Transitioning to Frailty, 689

FALLS
A Study Design to Investigate the Effect of Intense Tai Chi in Reducing

Falls among Older Adults Transitioning to Frailty, 689

FATTY ACID SUPPLEMENTATION
The Childhood Asthma Prevention Study (CAPS): Design and Research Protocol of a Randomized Trial for the Primary Prevention of Asthma, 333

FOLLOW-UP
Cause-Specific Mortality Coding: Methods in the Collaborative Ocular Melanoma Study COMS Report No. 14, 248
Closeout of Four Phase II Vanguard Trials and Patient Rollover into a Large International Phase III HIV Clinical Endpoint Trial, 42
The Closeout Process for a Clinical Trial Terminated Early for Lagging Enrollment and Inadequate Follow-up, 49
Locating Study Subjects: Predictors and Successful Search Strategies with Inmates Released from a U.S. County Jail, 238
Obtaining Event Status at the Close of the Treatment of Mild Hypertension Study: Methods and Implications for Other Trials, 56

FRAUD
The Clinical Trial: Deceitful, Disputable, Unbelievable, Unhelpful, and Shameful—What Next?, 593

GENERALIZED ESTIMATING EQUATIONS (GEE)
Sample Size and Power Calculations with Correlated Binary Data, 211

GENETIC ANALYSIS
Genetic Analysis in the Asthma Clinical Research Network, 196S

HEAD AND NECK CANCER
Individual Patient- versus Literature-Based Meta-analysis of Survival Data: Time to Event and Event Rate at a Particular Time Can Make a Difference, an Example Based on Head and Neck Cancer, 538

HEMODIALYSIS
Estimation and Comparison of Rates of Change in Repeated-Measures Studies with Planned Dropout, 620

HISTORICAL CONTROL STUDIES
Uniform Power Method for Sample Size Calculation in Historical Control Studies with Binary Response, 390

HIV
ACTG (AIDS Clinical Trials Group) 384: A Strategy Trial Comparing Consecutive Treatments for HIV-1, 143
Closeout of Four Phase II Vanguard Trials and Patient Rollover into a Large International Phase III HIV Clinical Endpoint Trial, 42
The Closeout Process for a Clinical Trial Terminated Early for Lagging Enrollment and Inadequate Follow-up, 49
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop, 485
An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1 Infection: Design, Rationale, and Methods of the Initio Trial, 160
Patient Notification and Follow-up after Suspension of Treatment Protocols: Experience from Four Clinical Trials of Treatments for AIDS-Related CMV Retinitis, 62
The Rationale and Design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial, 176
Viral Load as a Primary Outcome in Human Immunodeficiency Virus Trials: A Review of Statistical Analysis Methods, 639

HOUSE DUST MITE
The Childhood Asthma Prevention Study (CAPS): Design and

Research Protocol of a Randomized Trial for the Primary Prevention of Asthma, 333

HYPERTENSION
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical Center Recruitment Experience, 659
Obtaining Event Status at the Close of the Treatment of Mild Hypertension Study: Methods and Implications for Other Trials, 56
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29
Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 674

INFORMED CONSENT
Adaptive Designs, Informed Consent, and the Ethics of Research, 203
The Clinical Trial: Deceitful, Disputable, Unbelievable, Unhelpful, and Shameful—What Next?, 593
Sociodemographic and Clinical Predictors of Participation in Two Randomized Trials: Findings from the Collaborative Ocular Melanoma Study COMS Report No. 7, 526

INHALED STEROIDS
The Clinical Trials in the Initial Five-Year Award Period of the Asthma Clinical Research Network, 126S
Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial, 420
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405

ISOTONIC REGRESSION
Isotonic Designs for Phase I Trials, 126

LIPID-LOWERING TREATMENT
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical Center Recruitment Experience, 659
Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 29
Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 674
Rationale and Design of the St. Francis Heart Study: A Randomized Clinical Trial of Atorvastatin Plus Antioxidants in Asymptomatic Persons with Elevated Coronary Calcification, 553

LOGISTIC REGRESSION
Sample Size and Power Calculations with Correlated Binary Data, 211

LONGITUDINAL STUDY METHODS
Locating Study Subjects: Predictors and Successful Search Strategies with Inmates Released from a U.S. County Jail, 238

LORAZEPAM
The Prehospital Treatment of Status Epilepticus (PHTSE) Study: Design and Methodology, 290

LUNG CANCER
Toward Less Futile Surgery in Non-Small Cell Lung Cancer? A Randomized Clinical Trial to Evaluate the Cost-Effectiveness of Positron Emission Tomography, 89

LUNG FUNCTION. *See* PULMONARY FUNCTION TESTING

MAXIMUM TOLERATED DOSE
Isotonic Designs for Phase I Trials, 126

META-ANALYSIS
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop, 485
Individual Patient- versus Literature-Based Meta-analysis of Survival Data: Time to Event and Event Rate

at a Particular Time Can Make a Difference, an Example Based on Head and Neck Cancer, 538

MINIMAX DESIGN
Graphical Search for Two-Stage Designs for Phase II Clinical Trials, 367
A Three-Outcome Design for Phase II Clinical Trials, 117

MINORITIES
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical Center Recruitment Experience, 659
Attrition and Retention of Ethnically Diverse Subjects in a Multicenter Randomized Controlled Research Trial, 236S
Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 674
Promoting Adherence and Retention to Clinical Trials in Special Populations: A Women's Health Initiative Workshop, 279
Recruitment of Participants for the Estrogen Replacement and Atherosclerosis (ERA) Trial: A Comparison of Costs, Yields, and Participant Characteristics from Community- and Hospital-Based Recruitment Strategies, 13
Recruitment Strategies in the Asthma Clinical Research Network, 222S
Sociodemographic and Clinical Predictors of Participation in Two Randomized Trials: Findings from the Collaborative Ocular Melanoma Study COMS Report No. 7, 526

MIXED EFFECTS
Summarizing Methacholine Challenges in Clinical Research, 244S

MODEM REMOTE SUPPORT
Modem Remote Support of Pulmonary-Function Testing and Quality Control Systems, 156S

MORTALITY CODING
Cause-Specific Mortality Coding: Methods in the Collaborative Ocular Melanoma Study COMS Report No. 14, 248

MULTISYMPTOM ILLNESSES
A Multicenter Two by Two Factorial Trial of Cognitive Behavioral Therapy and Aerobic Exercise for Gulf War Veterans' Illnesses: Design of a Veterans Affairs Cooperative Study (CSP #470), 310

MYOPIA
The Correction of Myopia Evaluation Trial (COMET): Design and General Baseline Characteristics, 573

NET HEALTH BENEFITS
Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data, 228

NUMBER NEEDED TO TREAT (NNT)
Calculating Confidence Intervals for the Number Needed to Treat, 102

OBESITY
Principles for Enhanced Recruitment of Subjects in a Large Clinical Trial: The XENDOS Study Experience, 515

OCULAR MELANOMA
Cause-Specific Mortality Coding: Methods in the Collaborative Ocular Melanoma Study COMS Report No. 14, 248
Sociodemographic and Clinical Predictors of Participation in Two Randomized Trials: Findings from the Collaborative Ocular Melanoma Study COMS Report No. 7, 526

OLDER ADULTS. *See* AGING

OPTIMAL DESIGN
Graphical Search for Two-Stage Designs for Phase II Clinical Trials, 367

PARTICIPANTS, RECRUITMENT OF
See RECRUITMENT

PEER REVIEW
The Clinical Trial: Deceitful, Disputable, Unbelievable, Unhelpful, and Shameful—What Next?, 593

PEST SOFTWARE
Comparison of the Two-Sided Single Triangular Test to the Double Triangular Test, 503

PHASE I CLINICAL TRIALS
Isotonic Designs for Phase I Trials, 126

PHASE II CLINICAL TRIALS
Graphical Search for Two-Stage Designs for Phase II Clinical Trials, 367
A Three-Outcome Design for Phase II Clinical Trials, 117

PLASMA CORTISOL MEASUREMENTS
The Clinical Trials in the Initial Five-Year Award Period of the Asthma Clinical Research Network, 126S

PNEUMOCOCCAL DISEASE
Design of a Group-Randomized *Streptococcus pneumoniae* Vaccine Trial, 438

POSITRON EMISSION TOMOGRAPHY
Toward Less Futile Surgery in Non-Small Cell Lung Cancer? A Randomized Clinical Trial to Evaluate the Cost-Effectiveness of Positron Emission Tomography, 89

POSTTRAUMATIC STRESS DISORDER
Design of Department of Veterans Affairs Cooperative Study No. 420: Group Treatment of Posttraumatic Stress Disorder, 74

POWER
Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data, 228
Sample Size and Power Calculations with Correlated Binary Data, 211
Sample Size Determination for Equivalence Test Using Rate Ratio of Sensitivity and Specificity in Paired Sample Data, 373
Uniform Power Method for Sample Size Calculation in Historical Control Studies with Binary Response, 390

PSYCHOTHERAPY RESEARCH
Design of Department of Veterans Affairs Cooperative Study No. 420: Group Treatment of Posttraumatic Stress Disorder, 74

PULMONARY FUNCTION TESTING
The Clinical Trials in the Initial Five-Year Award Period of the Asthma Clinical Research Network, 126S
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405
Modem Remote Support of Pulmonary-Function Testing and Quality Control Systems, 156S

QUALITY ASSURANCE
Adaptive Double Data Entry: A Probabilistic Tool for Choosing Which Forms to Reenter, 2
Data Management Procedures in the Asthma Clinical Research Network, 168S
Genetic Analysis in the Asthma Clinical Research Network, 196S
Modem Remote Support of Pulmonary-Function Testing and Quality Control Systems, 156S
Quality Control within the Asthma Clinical Research Network, 207S

RANDOMIZATION PROCEDURES
Implementing Randomization Procedures in the Asthma Clinical Research Network, 181S

RATES OF CHANGE
Estimation and Comparison of Rates of Change in Repeated-Measures Studies with Planned Dropout, 620

RECONSENT
Closeout of Four Phase II Vanguard Trials and Patient Rollover into a Large International Phase III HIV Clinical Endpoint Trial, 42

RECRUITMENT
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical Center Recruitment Experience, 659
Locating Study Subjects: Predictors and Successful Search Strategies with Inmates Released from a U.S. County Jail, 238
Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 674
Principles for Enhanced Recruitment of Subjects in a Large Clinical Trial: The XENDOS Study Experience, 515
Recruitment of Participants for the Estrogen Replacement and Atherosclerosis (ERA) Trial: A Comparison of Costs, Yields, and Participant Characteristics from Community- and Hospital-Based Recruitment Strategies, 13
Recruitment Strategies in the Asthma Clinical Research Network, 222S
Sociodemographic and Clinical Predictors of Participation in Two Randomized Trials: Findings from the Collaborative Ocular Melanoma Study COMS Report No. 7, 526

REGISTRATION TRIALS
Clinical Trials for Drug Registrations in Asian-Pacific Countries: Proposal for a New Paradigm from a Statistical Perspective, 357

REPEATED-MEASURES DATA
Estimation and Comparison of Rates of Change in Repeated-Measures Studies with Planned Dropout, 620

RETENTION
Attrition and Retention of Ethnically Diverse Subjects in a Multicenter Randomized Controlled Research Trial, 236S
Promoting Adherence and Retention to Clinical Trials in Special Populations: A Women's Health Initiative Workshop, 279

SAMPLE SIZE
Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data, 228
Sample Size and Power Calculations with Correlated Binary Data, 211
Sample Size Determination for Equivalence Test Using Rate Ratio of Sensitivity and Specificity in Paired Sample Data, 373
Uniform Power Method for Sample Size Calculation in Historical Control Studies with Binary Response, 390

SANDWICH ESTIMATOR
Sample Size and Power Calculations with Correlated Binary Data, 211

SELF-DESIGNING TRIALS
A Self-Designing Rule for Clinical Trials with Arbitrary Response Variables, 111

SENSITIVITY
Sample Size Determination for Equivalence Test Using Rate Ratio of Sensitivity and Specificity in Paired Sample Data, 373

SEQUENTIAL METHODS
Comparison of the Two-Sided Single Triangular Test to the Double Triangular Test, 503
A Three-Outcome Design for Phase II Clinical Trials, 117

SITE VISITS
Quality Control within the Asthma Clinical Research Network, 207S

SPECIFICITY
Sample Size Determination for Equivalence Test Using Rate

Ratio of Sensitivity and Specificity in Paired Sample Data, 373

SPIROMETRY
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405
Modem Remote Support of Pulmonary-Function Testing and Quality Control Systems, 156S

STATUS EPILEPTICUS
The Prehospital Treatment of Status Epilepticus (PHTSE) Study: Design and Methodology, 290

STEROIDS
The Clinical Trials in the Initial Five-Year Award Period of the Asthma Clinical Research Network, 126S
Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial, 420
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design, 405

STRATIFICATION
Implementing Randomization Procedures in the Asthma Clinical Research Network, 181S

SUBGROUP ANALYSIS
Trials within Trials: Confirmatory Subgroup Analyses in Controlled Clinical Experiments, 605

SURROGATE ENDPOINTS
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop, 485

TAI CHI
A Study Design to Investigate the Effect of Intense Tai Chi in Reducing Falls among Older Adults Transitioning to Frailty, 689

THREE-OUTCOME DESIGN
A Three-Outcome Design for Phase II Clinical Trials, 117

TRAINING
Quality Control within the Asthma Clinical Research Network, 207S

TRIANGULAR TEST
Comparison of the Two-Sided Single Triangular Test to the Double Triangular Test, 503

TUBERCULOSIS
Locating Study Subjects: Predictors and Successful Search Strategies with Inmates Released from a U.S. County Jail, 238

UNIFORM POWER
Uniform Power Method for Sample Size Calculation in Historical Control Studies with Binary Response, 390

UP-AND-DOWN METHOD
Isotonic Designs for Phase I Trials, 126

VACCINES
Design of a Group-Randomized *Streptococcus pneumoniae* Vaccine Trial, 438

VISUAL ACUITY
The Correction of Myopia Evaluation Trial (COMET): Design and General Baseline Characteristics, 573

WOMEN'S HEALTH
Promoting Adherence and Retention to Clinical Trials in Special Populations: A Women's Health Initiative Workshop, 279
Recruitment of Participants for the Estrogen Replacement and Atherosclerosis (ERA) Trial: A Comparison of Costs, Yields, and Participant Characteristics from Community- and Hospital-Based Recruitment Strategies, 13
Recruitment Strategies in the Asthma Clinical Research Network, 222S

WORKSHOP PROCEEDINGS
Promoting Adherence and Retention to Clinical Trials in Special Populations: A Women's Health Initiative Workshop, 279